The following IPOs are expected to price this week:
AcelRx (ACRX), a biotech developing a Phase 3 treatment for acute post-operative pain, plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14. At the mid-point of the proposed range, AcelRx will command a market value of $210 million. The Redwood City, CA-based company, which was founded in 2005 and has yet to generate product revenue, plans to list on the NASDAQ under the symbol ACRX. Piper Jaffray is the lead underwriter on the deal.
BioHorizons (BHZN), which sells dental implants and biologics for the replacement of missing teeth, plans to raise $90 million by offering 5.6 million shares at a price range of $15 to $17. At the mid-point of the proposed range, BioHorizons will command a market value of $315 million. BioHorizons, which was founded in 1995, booked $78 million in sales over the last 12 months. The Birmingham, AL-based company plans to list on the NASDAQ under the symbol BHZN. Piper Jaffray and Jefferies & Co. are the lead underwriters on the deal.
China Century Dragon Media (CDM), a TV advertising company that resells ad time on China Central Television, plans to raise $9 million by offering 2.5 million shares at a price range of $3.00 to $4.00. At the mid-point of the proposed range, China Century Dragon Media will command a market value of $57 million. The Huizhou City-based company, which was founded in 2007, booked $106 million in sales over the last 12 months. The company plans to list on the NYSE under the symbol CDM. WestPark Capital and i-Bankers Securities are the lead underwriters on the deal.
Endocyte (ECYT), which is developing EC145 (entering Phase III) for the treatment of ovarian cancer, plans to raise $75 million by offering 5.35 million shares at a price range of $13 to $15. At the mid-point of the proposed range, Endocyte will command a market value of $269 million. The West Lafayette, IN-based company, which was founded in 1995 and has yet to generate product revenue, plans to list on the NASDAQ under the symbol ECYT. RBC Capital Markets and Leerink Swann are the lead underwriters on the deal.
Epocrates (EPOC), which provides an ad-supported mobile drug reference app for healthcare professionals, plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the mid-point of the proposed range, Epocrates will command a market value of $344 million. Epocrates, which was founded in 1998, booked $101 million in sales over the last 12 months. The San Mateo, CA-based company plans to list on the NASDAQ under the symbol EPOC. J.P. Morgan and Piper Jaffray are the lead underwriters on the deal.
Imperial Holdings (IFT), a specialty finance firm originating loans collateralized by life insurance policies, plans to raise $250 million by offering 16.7 million shares at a price range of $14 to $16. At the mid-point of the proposed range, Imperial Holdings will command a market value of $304 million. The Boca Raton, FL-based company, which was founded in 2006 and booked $97 million in sales over the last 12 months, plans to list on the NYSE under the symbol IFT. FBR Capital Markets, JMP Securities and Wunderlich Securities are the lead underwriters on the deal.
MedQuist Holdings (MEDH), which provides integrated clinical documentation solutions to over 2,400 hospitals and clinics in the US, plans to raise $86 million by offering 7.8 million shares at a price range of $10 to $12. At the mid-point of the proposed range, MedQuist will command a market value of $562 million. MedQuist, which was founded in 1998, booked $407 million in sales over the last 12 months. The Franklin, TN-based company plans to list on the NASDAQ under the symbol MEDH. Lazard Capital Markets, Macquarie Capital and RBC Capital Markets are the lead underwriters on the deal.
NeoPhotonics (NPTN), which is a leading supplier of photonic-based optical modules and subystems, plans to raise $70 million by offering 7 million shares at a price range of $9 to $11. At the mid-point of the proposed range, NeoPhotonics will command a market value of $238 million. NeoPhotonics, which was founded in 1996, booked $176 million in sales over the last 12 months. The San Jose, CA-based company plans to list on the NYSE under the symbol NPTN. BofA Merrill Lynch and Deutsche Bank Securities are the lead underwriters on the deal.
Pacira Pharmaceuticals (PCRX), which is developing a non-opioid postsurgical analgesic pending FDA approval, plans to raise $64 million by offering 4.25 million shares at a price range of $14 to $16. At the mid-point of the proposed range, Pacira Pharmaceuticals will command a market value of $252 million. Pacira Pharmaceuticals, which was founded in 2006, booked $17 million in sales over the last 12 months. The Parsippany, NJ-based company plans to list on the NASDAQ under the symbol PCRX. Barclays Capital and Piper Jaffray are the lead underwriters on the deal.
Tornier (TRNX), which makes orthopedic implants for upper and lower extremity joints, plans to raise $175 million by offering 8.75 million shares at a price range of $19 to $21. At the mid-point of the proposed range, Tornier will command a market value of $766 million. Tornier, which was founded in 1940, booked $223 million in sales over the last 12 months. The Amsterdam-based company plans to list on the NASDAQ under the symbol TRNX. BofA Merrill Lynch and J.P. Morgan are the lead underwriters on the deal.
Trunkbow International Holdings (TBOW), a Chinese provider of mobile applications to telecom operators formed through a reverse merger, plans to raise $30 million by offering 5 million shares at a price range of $5 to $7, with a proposed market value of $225 million. Trunkbow, which was founded in 2010, booked $13 million in sales over the last 12 months. The Beijing-based company plans to list on the NASDAQ under the symbol TBOW. Roth Capital is the lead underwriter on the deal.
Zuoan Fashion Limited (ZA), a Chinese designer and distributor of casual menswear through 1,075 retail outlets, plans to raise $79 million by offering 6.9 million shares at a price range of $10.50 to $12.50. At the mid-point of the proposed range, Zuoan Fashion Limited will command a market value of $326 million. Zuoan Fashion Limited, which was founded in 1999, booked $104 million in sales over the last 12 months. The Shanghai-based company plans to list on the NYSE under the symbol ZA. Cowen & Company is the lead underwriter on the deal.
Last week, there were 7 IPO pricings. Velti (VELT), a global provider of mobile advertising and marketing software solutions, was the week's winner, ending up 30% from its IPO price.
